JP5683265B2 - 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法 - Google Patents

補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法 Download PDF

Info

Publication number
JP5683265B2
JP5683265B2 JP2010511295A JP2010511295A JP5683265B2 JP 5683265 B2 JP5683265 B2 JP 5683265B2 JP 2010511295 A JP2010511295 A JP 2010511295A JP 2010511295 A JP2010511295 A JP 2010511295A JP 5683265 B2 JP5683265 B2 JP 5683265B2
Authority
JP
Japan
Prior art keywords
antibody
complement
seq
antigen
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010511295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504872A5 (enExample
JP2011504872A (ja
Inventor
ルッカーレン カンパーニュ， メノ ファン
ルッカーレン カンパーニュ， メノ ファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39712089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5683265(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2011504872A publication Critical patent/JP2011504872A/ja
Publication of JP2011504872A5 publication Critical patent/JP2011504872A5/ja
Application granted granted Critical
Publication of JP5683265B2 publication Critical patent/JP5683265B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
JP2010511295A 2007-06-07 2008-06-04 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法 Expired - Fee Related JP5683265B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93372107P 2007-06-07 2007-06-07
US60/933,721 2007-06-07
US5506808P 2008-05-21 2008-05-21
US60/055,068 2008-05-21
PCT/US2008/065771 WO2008154251A2 (en) 2007-06-07 2008-06-04 C3b antibodies and methods for the prevention and treatment of complement- associated disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014020001A Division JP5980249B2 (ja) 2007-06-07 2014-02-05 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法

Publications (3)

Publication Number Publication Date
JP2011504872A JP2011504872A (ja) 2011-02-17
JP2011504872A5 JP2011504872A5 (enExample) 2011-06-02
JP5683265B2 true JP5683265B2 (ja) 2015-03-11

Family

ID=39712089

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010511295A Expired - Fee Related JP5683265B2 (ja) 2007-06-07 2008-06-04 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法
JP2014020001A Expired - Fee Related JP5980249B2 (ja) 2007-06-07 2014-02-05 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法
JP2016145975A Pending JP2016204382A (ja) 2007-06-07 2016-07-26 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014020001A Expired - Fee Related JP5980249B2 (ja) 2007-06-07 2014-02-05 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法
JP2016145975A Pending JP2016204382A (ja) 2007-06-07 2016-07-26 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法

Country Status (18)

Country Link
US (2) US8012473B2 (enExample)
EP (1) EP2162470A2 (enExample)
JP (3) JP5683265B2 (enExample)
KR (3) KR20170023212A (enExample)
CN (1) CN101809034B (enExample)
AR (1) AR066916A1 (enExample)
AU (1) AU2008262048B2 (enExample)
BR (1) BRPI0812767A2 (enExample)
CA (1) CA2690124A1 (enExample)
CL (1) CL2008001656A1 (enExample)
IL (1) IL201820A0 (enExample)
MX (1) MX2009013082A (enExample)
PE (1) PE20090416A1 (enExample)
RU (1) RU2473563C2 (enExample)
SG (2) SG10201608952QA (enExample)
TW (2) TWI441832B (enExample)
WO (1) WO2008154251A2 (enExample)
ZA (1) ZA200907575B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2044111E (pt) 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
PE20091388A1 (es) * 2007-11-02 2009-09-24 Novartis Ag Moleculas y metodos para modular el componente de complemento
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
ME01699B (me) 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
ES2594893T3 (es) * 2009-12-16 2016-12-23 Abbvie Biotherapeutics Inc. Anticuerpos anti HER2 y sus usos
US20130084584A1 (en) * 2010-03-31 2013-04-04 Anna Blom Method to detect tissue degradation leading to inflammation
ES2717912T3 (es) 2010-05-14 2019-06-26 Univ Colorado Regents Grupos dirigidos al receptor del complemento 2 (cr2) mejorados
USRE49339E1 (en) 2010-06-22 2022-12-20 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3D fragment of complement component 3
CA2821067C (en) 2010-11-29 2019-06-04 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CA2869477C (en) * 2012-04-03 2020-06-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor c3 antibodies and uses thereof
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
CA2899034A1 (en) * 2013-01-23 2014-07-31 Musc Foundation For Research Development Targeting constructs based on natural antibodies and uses thereof
BR112016002435A8 (pt) 2013-08-07 2020-09-29 Alexion Pharma Inc proteínas biomarcadoras da síndrome urêmica hemolítica atípica
US10183989B2 (en) * 2013-12-24 2019-01-22 Novelmed Therapeutics, Inc. Methods of treating ocular diseases
BR112016019286B1 (pt) * 2014-02-26 2024-02-20 Allergan, Inc. Anticorpo anti-c5
AU2015223056B2 (en) 2014-02-27 2020-10-01 Allergan, Inc. Complement Factor Bb antibodies
KR101981532B1 (ko) 2014-06-12 2019-09-02 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
BR122023020102A2 (pt) * 2014-08-20 2023-12-12 Stichting Sanquin Bloedvoorziening Anticorpos de potenciamento do fator h e seus usos
WO2016123371A1 (en) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
RU2584582C1 (ru) * 2015-03-16 2016-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Моноклональное антитело сс3-4 к конформационному эпитопу с3 человека, штамм гибридной днк мыши рккк(п)764д - продуцент моноклонального антитела сс3-4
TWI745320B (zh) 2015-12-16 2021-11-11 美商Ｒａ製藥公司 補體活性之調節劑
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
SG11201907606XA (en) * 2017-02-27 2019-09-27 Regeneron Pharma Humanized model of kidney and liver disorders
CA3084043A1 (en) 2017-12-04 2019-06-13 Ra Pharmaceuticals, Inc. Modulators of complement activity
GB201800620D0 (en) * 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
AR117565A1 (es) 2018-04-03 2021-08-18 Ngm Biopharmaceuticals Inc Agentes de unión a c3 y método de uso de los mismos
RU2687609C1 (ru) * 2018-05-30 2019-05-15 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
EP3801772A1 (en) 2018-06-11 2021-04-14 Aarhus Universitet Single domain antibodies for complement regulation
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
WO2020185541A2 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
CA3134614A1 (en) 2019-03-29 2020-10-08 Ra Pharmaceuticals, Inc. Complement modulators and related methods
MX2021013010A (es) 2019-04-24 2022-01-18 Ra Pharmaceuticals Inc Composiciones y metodos para modular la actividad del complemento.
CA3147638A1 (en) 2019-07-17 2021-01-21 Gemini Therapeutics Sub, Inc. Factor h potentiating antibodies and uses thereof
AR128065A1 (es) 2021-12-22 2024-03-20 Cdr Life Ag Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
KR20230105972A (ko) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
KR20250018169A (ko) * 2022-04-29 2025-02-04 브로드윙 바이오 엘엘씨 이중특이적 항체 및 안구 질환의 치료 방법
CN117624347A (zh) 2022-08-30 2024-03-01 天辰生物医药(苏州)有限公司 抗人补体c5抗体以及其融合蛋白
WO2024064732A2 (en) * 2022-09-20 2024-03-28 Visterra, Inc. Treatment of complement mediated diseases and disorders with c3b-antibodies
JP2025537300A (ja) 2022-11-10 2025-11-14 ロングバイオ ファーマ （スーチョウ） カンパニー、リミテッド 補体阻害ハイブリッドタンパク質突然変異体および抗体とその融合タンパク質
WO2024227154A1 (en) * 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
WO1994028159A1 (en) * 1993-05-31 1994-12-08 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
AU726187B2 (en) * 1996-03-07 2000-11-02 Imutran Limited Down-regulation resistant C3 convertase
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
BRPI9909220B1 (pt) * 1998-02-20 2018-09-18 Genentech Inc hibridoma, anticorpo monoclonal, anticorpo humanizado, anticorpo quimérico, anticorpo desimunizado ou fragmento de tais anticorpos
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
US8420783B2 (en) * 2004-12-08 2013-04-16 Immunomedics, Inc. Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof

Also Published As

Publication number Publication date
WO2008154251A4 (en) 2009-07-09
MX2009013082A (es) 2010-01-15
TW200911827A (en) 2009-03-16
CN101809034B (zh) 2015-07-08
US8012473B2 (en) 2011-09-06
TWI557137B (zh) 2016-11-11
JP5980249B2 (ja) 2016-08-31
IL201820A0 (en) 2010-06-16
SG182165A1 (en) 2012-07-30
US20120128674A1 (en) 2012-05-24
KR101572700B1 (ko) 2015-11-30
AU2008262048B2 (en) 2013-09-26
SG10201608952QA (en) 2016-12-29
BRPI0812767A2 (pt) 2014-12-02
CA2690124A1 (en) 2008-12-18
KR20170023212A (ko) 2017-03-02
KR20150029002A (ko) 2015-03-17
KR20100041743A (ko) 2010-04-22
EP2162470A2 (en) 2010-03-17
AR066916A1 (es) 2009-09-23
TWI441832B (zh) 2014-06-21
CL2008001656A1 (es) 2009-05-22
US20090081211A1 (en) 2009-03-26
RU2009149385A (ru) 2011-07-20
US8377437B2 (en) 2013-02-19
JP2014088434A (ja) 2014-05-15
AU2008262048A1 (en) 2008-12-18
PE20090416A1 (es) 2009-04-18
RU2473563C2 (ru) 2013-01-27
TW201441255A (zh) 2014-11-01
JP2016204382A (ja) 2016-12-08
ZA200907575B (en) 2011-02-23
WO2008154251A3 (en) 2009-05-14
JP2011504872A (ja) 2011-02-17
WO2008154251A2 (en) 2008-12-18
CN101809034A (zh) 2010-08-18

Similar Documents

Publication Publication Date Title
JP5980249B2 (ja) 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法
RU2522976C2 (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
US20180037667A1 (en) Anti-factor b antibodies and their uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141003

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150113

R150 Certificate of patent or registration of utility model

Ref document number: 5683265

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees